COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
COMPASS Pathways (Nasdaq: CMPS) announced its plans to release financial results for Q4 and year-end 2022 on February 28, 2023. Alongside the financial results, the company will update investors on recent business developments. A conference call will be held at 8:00 AM ET (1:00 PM UK), where the management team will discuss these updates. The call can be accessed by pre-registering, and a live webcast will also be available on the company's website. COMPASS specializes in mental health innovation, focusing on psilocybin therapy with its proprietary formulation, COMP360, designated as a Breakthrough Therapy by the FDA.
- COMP360 designated as a Breakthrough Therapy by FDA.
- Initiated phase 3 clinical program for treatment-resistant depression (TRD), largest of its kind.
- Phase 2b study showed significant improvement in depressive symptoms with COMP360.
- None.
Conference call to be held at 8:00am ET (1:00pm UK)
LONDON, Feb. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2022, and provide an update on recent business developments on 28 February 2023.
The management team will host a conference call at 8:00am ET (1:00pm UK) on 28 February. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on COMPASS Pathway’s website at: Fourth Quarter 2022 Financial Results
The webcast will also be available on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days.
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP 360 psilocybin therapy in TRD, the largest randomised, controlled, double-blind psilocybin therapy clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also conducting phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com
Availability of other information about COMPASS Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Enquiries
Media: Amy Lawrence, amy@compasspathways.com, +44 7813 777 919
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
FAQ
When will COMPASS Pathways release its Q4 2022 financial results?
What is the significance of COMP360 for COMPASS Pathways?
What time is the conference call on February 28, 2023?
How can I access the live webcast for COMPASS Pathways' conference call?
What recent developments will COMPASS Pathways discuss during the conference call?
